Long-term AZT Exposure Alters the Metabolic Capacity of Cultured Human Lymphoblastoid Cells
Open Access
- 27 January 2010
- journal article
- research article
- Published by Oxford University Press (OUP) in Toxicological Sciences
- Vol. 115 (1) , 109-117
Abstract
The antiretroviral efficacy of 3′-azido-3′-deoxythymidine (AZT) is dependent upon intracellular mono-, di-, and triphosphorylation and incorporation into DNA in place of thymidine. Thymidine kinase 1 (TK-1) catalyzes the first step of this pathway. MOLT-3, human lymphoblastoid cells, were exposed to AZT continuously for 14 passages (P1–P14) and cultured for an additional 14 passages (P15–P28) without AZT. Progressive and irreversible depletion of the enzymatically active form of the TK-1 24-kDa monomer with loss of active protein was demonstrated during P1–P5 of AZT exposure. From P15 to P28, both the 24- and the 48-kDa forms of TK-1 were undetectable and a tetrameric 96-kDa form was present. AZT-DNA incorporation was observed with values of 150, 133, and 108 molecules of AZT/106 nucleotides at the 10μM plasma-equivalent AZT dose at P1, P5, and P14, respectively. An exposure-related increase in the frequency of micronuclei (MN) was observed in cells exposed to either 10 or 800μM AZT during P1–P14. Analysis of the cell cycle profile revealed an accumulation of S-phase cells and a decrease in G1-phase cells during exposure to 800μM AZT for 14 passages. When MOLT-3 cells were grown in AZT-free media (P15–P29), there was a reduction in AZT-DNA incorporation and MN formation; however, TK-1 depletion and the persistence of S-phase delay were unchanged. These data suggest that in addition to known mutagenic mechanisms, cells may become resistant to AZT partially through inactivation of TK-1 and through modulation of cell cycle components.Keywords
This publication has 40 references indexed in Scilit:
- Centrosome amplification induced by the antiretroviral nucleoside reverse transcriptase inhibitors lamivudine, stavudine, and didanosineEnvironmental and Molecular Mutagenesis, 2009
- Reversible tetramerization of human TK1 to the high catalytic efficient form is induced by pyrophosphate, in addition to tripolyphosphates, or high enzyme concentrationThe FEBS Journal, 2008
- Cardiac-Targeted Transgenic Mutant Mitochondrial Enzymes: mtDNA Defects, Antiretroviral Toxicity and CardiomyopathyCardiovascular Toxicology, 2008
- Human inter-individual variability in metabolism and genotoxic response to zidovudineToxicology and Applied Pharmacology, 2008
- Micronucleated erythrocyte frequency in control and azidothymidine-treated Tk+/+, Tk+/− and Tk−/− miceMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2005
- 2′, 3′-Dideoxycytidine represses thymidine kinases 1 and 2 expression in T-lymphoid cellsLife Sciences, 2004
- Genetic damage detected in CD‐1 mouse pups exposed perinatally to 3′‐azido‐3′‐deoxythymidine or dideoxyinosine via maternal dosing, nursing, and direct gavage: II. Effects of the individual agents compared to combination treatmentEnvironmental and Molecular Mutagenesis, 2004
- Selective assays for thymidine kinase 1 and 2 and deoxycytidine kinase and their activities in extracts from human cells and tissuesBiochemical and Biophysical Research Communications, 1992
- Clinical Pharmacology of 3'-Azido-2',3'-Dideoxythymidine (Zidovudine) and Related DideoxynucleosidesNew England Journal of Medicine, 1989
- The Toxicity of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related ComplexNew England Journal of Medicine, 1987